Biomarin Pharmaceutical

At a glance

Biomarin Pharmaceutical reported 2025 revenue of $3.22B, up 12.9% from $2.85B in 2024. Over 4 years since 2021 ($1.85B), that is growth of about 14.9% a year. Operating margin was 12.7%, up from -4.5% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021.

In the last 12 months 3 insiders reported 0 open-market purchases and 5 sales ($4.3M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $1.6M by EVP, Chief Legal Officer George Eric Davis on Feb 26, 2026.

Biomarin Pharmaceutical filed 22 current reports (Form 8-K) in the last 12 months, most often for results of operations (6), material agreement (6), other events (6) and officer or director change (3). The latest officer or director change was reported on Sep 14, 2026. It reported a material agreement or a completed acquisition or disposal 6 times.

3 of the 20 investors tracked here held Biomarin Pharmaceutical at the last quarter end, worth $477.4M combined. It is the largest weight for Viking Global Investors (1.2% of its portfolio), followed by Bridgewater Associates (0.1%). Added: Viking Global Investors and Bridgewater Associates. Reduced: Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.